Jupiter Neurosciences, Inc. issued a statement on February 4, 2025, addressing recent market volatility and reassuring investors of no undisclosed material developments. The company emphasized its focus on advancing clinical and commercial milestones.
Chairman and CEO Christer Rosén highlighted the planned Direct-to-Consumer product launch later in 2025, which is expected to generate near-term revenues. This initiative aims to diversify the company's business model and provide immediate cash flow.
The company also confirmed securing $1.76 million in NIH funding and having an additional $16 million in grants under review. These funding sources, alongside the $11 million raised in the December 2024 IPO, position the company to advance its clinical and commercial initiatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.